Aphria Inc (TSX:APHA) Investors: Pay Attention to These 3 Things

Aphria Inc (TSX:APHA)(NYSE:APHA) has a terrible third quarter. Not only is the company struggling to boost production, but costs are also on the rise. As we head into the fourth quarter, be sure to monitor these three trends.

edit Jars of marijuana

Image source: Getty Images

Aphria Inc (TSX:APHA)(NYSE:APHA) stock is under fire. After reporting third quarter earnings, shares fell by 20%.

Based on nearly any metric, the quarter was horrendous. Aphria struggled to bring new production online, experienced rising corporate and packaging costs, and took a $50 million write-down on its newly acquired Latin America assets.

As we head into the fourth quarter, here are three important trends to monitor.

Production guidance

Demand for cannabis worldwide continues to explode. By 2030, Canadian demand could reach $10 billion annually while the U.S. could surpass $40 billion. To meet this heavy growth, cannabis growers are scrambling to ramp production quickly.

Aphria’s management team has revealed its plans to eventually reach $1 billion in annual sales, but recent quarters have thrown that lofty goal into doubt. In fact, the company now anticipates flat revenue growth for the fourth quarter. What happened?

It turns out that scaling commercial-grade facilities in under 12 months is extraordinarily difficult. We’ve seen other disrupters like Elon Musk attempt similar feats and fail.

If Aphria can’t ramp its production this year, it will be leaving millions of dollars on the table. While new production facilities won’t come online until the second half of 2019, pay close attention to the details when management updates its anticipated production growth.

Cost controls

While scaling production can be difficult, doing it in a cost-efficient manner is even more troublesome.

Last quarter, Aphria’s corporate costs went up across the board. Not only did it need to expand its employee count, but Aphria also failed to automate most of its production as promised.

Incredibly, most of its packaging is still done by hand. If it can’t figure out how to automate this core process, Aphria will struggle to bring down costs alongside its competitors.

In April, company executives specifically highlighted their new focus on “automation and the development of new growing facilities,” but declined to give an exact date by which investors should expect these upgrades, instead noting that they are “mid-term” priorities.

Aphria’s management team keeps pushing its cost-cutting efforts into the future, but if it wants to win back the trust of investors, it needs to provide a solid plan for boosting margins.

Short sellers

Short sellers, investors who bet that a stock will fall in value, can wreak havoc in an instant. While many investors choose to ignore short sellers, pegging them as opportunists, it’s critical that you hear and judge their arguments for yourself.

Earlier this year, Quintessential Capital released a report evaluating Aphria’s stock following months of research, including visits to the company’s facilities in Jamaica, Argentina, and Colombia. The conclusion was dire.

Quintessential Capital charged Aphria insiders with creating and buying shell companies, changing their names and then selling them to Aphria at artificially-inflated prices.

The fact that Aphria has already taken a multi-million dollar write-down on its Latin America acquisition adds considerable credence to these allegations.

If Quintessential Capital is correct, there could be at least $200 million in additional write-offs to come.

You can bet that Quintessential Capital will be looking to push more damning information about Aphria public over the next few months. You’ll want to pay attention to anything else they reveal.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Ryan Vanzo has no position in any stocks mentioned.

More on Cannabis Stocks

Pot stocks are a riskier investment
Cannabis Stocks

Is the Worst Over for Canopy Growth Stock?

Down 99% from all-time highs Canopy Growth stock has burnt investor wealth and remains a high-risk investment.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Steer Clear: This Stock Spells Trouble

A newly listed cannabis stock is outperforming in 2024 but investors should stay clear to avoid trouble and losses.

Read more »

Cannabis stocks have fallen.
Cannabis Stocks

2 Best Marijuana Stocks to Buy This Month

Marijuana stocks in the U.S. such as Green Thumb and Curaleaf can help you deliver outsized gains to investors in…

Read more »

A cannabis plant grows.
Cannabis Stocks

Can Aurora Cannabis Stock Recover in 2024?

Aurora Cannabis stock is down 99% from all-time highs but remains a high-risk bet, despite its cheap valuation.

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

The Best Cannabis Stock to Buy Right Now

This cannabis stock has jumped 30% in the last few months, with even more growth on the way – all…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Down 99% From All-Time Highs, Is Canopy Growth Stock a Good Buy Right Now?

Canopy Growth stock is a high-risk investment due to its negative profit margins and challenging liquidity position.

Read more »

Marijuana plant and cannabis oil bottles isolated
Stocks for Beginners

Aurora Cannabis’ Reverse Stock Split: Is the Stock a Buy Today?

Cannabis stock Aurora (TSX:ACB) is consolidating shares once again, but what does this mean for investors?

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Where Will Cannabis Stocks Be in 10 Years?

Cannabis stocks could see a huge shift upwards should marijuana be rescheduled in the U.S., but you can still buy…

Read more »